Current Behavioral Neuroscience Reports

, Volume 6, Issue 4, pp 219–226 | Cite as

Subjective Cognitive Decline and Biomarkers of Preclinical Alzheimer’s Disease

  • Sepideh ShokouhiEmail author
  • Kimberly Albert
Geropsychiatry & Cognitive Disorders of Late Life (P Newhouse, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Geropsychiatry & Cognitive Disorders of Late Life


Purpose of Review

Here, we have provided an overview of previous biomarker studies to support the importance of subjective cognitive decline (SCD) in early identification of at-risk subjects and differentiation between normal and pathological aging, including Alzheimer’s disease (AD). We have identified several major areas that would require future research to address current gaps in knowledge and increase the value of SCD in preclinical AD.

Recent Findings

SCD in clinically normal individuals has received increasing attention by clinicians and AD researchers. SCD is etiologically heterogeneous. Biomarker studies have and will continue to increase our knowledge of the biological factors contributing to the manifestation and progression of SCD in AD.


Future research with current and new generations of biomarkers is needed to disentangle the biological basis of SCD, improve the utility of SCD for early AD diagnosis, and understand factors that influence SCD characteristics, including sex differences and cognitive reserve.


Subjective cognitive decline Preclinical Alzheimer’s disease Amyloid Tau Neurodegeneration Functional neuroimaging 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kahn RL, et al. Memory complaint and impairment in the aged: the effect of depression and altered brain function. JAMA Psychiat. 1975;32(12):1569–73. Scholar
  2. 2.
    Perlin S, Butler R. Psychiatric aspects of adaptation to the aging experience. In: Human aging: biological and behavioral aspects. Bethesda: Public Health Service Publication; 1962. p. 143–58.Google Scholar
  3. 3.
    • Reisberg B, et al. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010;6(1):11–24. study followed up subjects for mean period of 6.8 years. The outcomes indicated that subjective cognitive decline in clinically normal elderly adults is a harbinger of future cognitive decline. CrossRefPubMedGoogle Scholar
  4. 4.
    Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130(6):439–51. Scholar
  5. 5.
    Aisen PS. Cognitive/clinical endpoints for pre-dementia AD trials. J Prev Alzheimers Dis. 2015;2(2):82–4. Scholar
  6. 6.
    Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961–70. Scholar
  7. 7.
    Frank LB. Commentary on “Health economics and the value of therapy in Alzheimer’s disease.” Report from the Alzheimer’s Association Research Roundtable on patient-reported outcomes and dementia research. Alzheimers Dement. 2007;3(3):162–5. Scholar
  8. 8.
    Rabin LA, et al. Subjective cognitive decline in older adults: an overview of self-report measures used across 19 international research studies. J Alzheimers Dis. 2015;48 Suppl 1(0 1):S63–86. Scholar
  9. 9.
    Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–52. Scholar
  10. 10.
    Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. Scholar
  11. 11.
    • Barnes LL, et al. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology. 2006;67(9):1581–5. paper represents one of the first studies that evaluated the associations between SCD and AD pathologies. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Jorm AF, Masaki KH, Davis DG, Hardman J, Nelson J, Markesbery WR, et al. Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease. Neurology. 2004;63(10):1960–1. Scholar
  13. 13.
    Kryscio RJ, Abner EL, Cooper GE, Fardo DW, Jicha GA, Nelson PT, et al. Self-reported memory complaints. Neurology. 2014;83(15):1359–65. Scholar
  14. 14.
    Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50(12):2880–6. Scholar
  15. 15.
    Amariglio RE, Buckley RF, Mormino EC, Marshall GA, Johnson KA, Rentz DM, et al. Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement. 2018;4:444–9. Scholar
  16. 16.
    Vogel JW, Varga Doležalová M, la Joie R, Marks SM, Schwimmer HD, Landau SM, et al. Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly. Neurology. 2017;89(19):2002–9. Scholar
  17. 17.
    Perrotin A, et al. Subjective cognition and amyloid deposition imaging: a Pittsburgh compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012;69(2):223–9. Scholar
  18. 18.
    Buckley RF, et al. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer’s disease. Alzheimers Dement. 2016;12(7):796–804. Scholar
  19. 19.
    Zwan MD, et al. Subjective memory complaints in APOE ɛ4 carriers are associated with high amyloid-β burden. J Alzheimers Dis. 2016;49(4):1115–22.CrossRefGoogle Scholar
  20. 20.
    Snitz BE, Weissfeld LA, Cohen AD, Lopez OL, Nebes RD, Aizenstein HJ, et al. Subjective cognitive complaints, personality and brain amyloid-beta in cognitively normal older adults. Am J Geriatr Psychiatry. 2015;23(9):985–93. Scholar
  21. 21.
    Amariglio RE, Mormino EC, Pietras AC, Marshall GA, Vannini P, Johnson KA, et al. Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology. 2015;85(1):56–62. Scholar
  22. 22.
    Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22(4):531–44. Scholar
  23. 23.
    Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8(1):1214. Scholar
  24. 24.
    •• Buckley RF, et al. Region-specific association of subjective cognitive decline with tauopathy independent of global β-amyloid burden. JAMA Neurol. 2017;74(12):1455–63. study showed that both amyloid and tau influence the manifestation of SCD (mainly memory domain) in clinically normal subjects without interaction. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Swinford CG, et al. Memory concerns in the early Alzheimer’s disease prodrome: regional association with tau deposition. Alzheimers Dement. 2018;10:322–31. Scholar
  26. 26.
    Hesse C, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297(3):187–90. Scholar
  27. 27.
    Striepens N, Scheef L, Wind A, Popp J, Spottke A, Cooper-Mahkorn D, et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord. 2010;29(1):75–81. Scholar
  28. 28.
    Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006;67(5):834–42. Scholar
  29. 29.
    Hu X, Teunissen CE, Spottke A, Heneka MT, Düzel E, Peters O, et al. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer’s disease—data from three memory clinic studies. Alzheimers Dement. 2018;15:185–93. Scholar
  30. 30.
    van der Flier WM, et al. Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. J Neurol. 2004;251(6):671–5. Scholar
  31. 31.
    Chao LL, et al. Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria. Neurobiol Aging. 2010;31(3):368–77. Scholar
  32. 32.
    Mosconi L, de Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008;63(6):609–18. Scholar
  33. 33.
    Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer’s disease. J Neurochem. 1983;41(1):266–72. Scholar
  34. 34.
    Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10(2):122–6. Scholar
  35. 35.
    Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;308(8000):1403. Scholar
  36. 36.
    Lehéricy S, Hirsch ÉC, Cervera-Piérot P, Hersh LB, Bakchine S, Piette F, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer’s disease. J Comp Neurol. 1993;330(1):15–31. Scholar
  37. 37.
    Newhouse PA. Cholinergic drug studies in dementia and depression. In: Zandi T, Ham RJ, editors. New directions in understanding dementia and Alzheimer’s disease. Boston: Springer US; 1990. p. 65–76.CrossRefGoogle Scholar
  38. 38.
    Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav. 2011;99(2):254–61. Scholar
  39. 39.
    Sarter M, Bruno JP. Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience. 1999;95(4):933–52. Scholar
  40. 40.
    Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol. 1974;30(2):113–21. Scholar
  41. 41.
    Mesulam MM, et al. Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6). Neuroscience. 1983;10(4):1185–201. Scholar
  42. 42.
    Heckers S, Mesulam MM. Two types of cholinergic projections to the rat amygdala. Neuroscience. 1994;60(2):383–97. Scholar
  43. 43.
    Mesulam M. The cholinergic lesion of Alzheimer’s disease: pivotal factor or side show? Learn Mem. 2004;11(1):43–9.CrossRefGoogle Scholar
  44. 44.
    Scheef L, Grothe MJ, Koppara A, Daamen M, Boecker H, Biersack H, et al. Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD). NeuroImage Clin. 2018;21:101612. Scholar
  45. 45.
    Delbeuck X, Van der Linden M, Collette F. Alzheimer’ disease as a disconnection syndrome? Neuropsychol Rev. 2003;13(2):79–92. Scholar
  46. 46.
    Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer’s disease. J Neurosci. 2009;29(6):1860–73. Scholar
  47. 47.
    Mohan A, et al. The significance of the default mode network (DMN) in neurological and neuropsychiatric disorders: a review. Yale J Biol Med. 2016;89(1):49–57.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Contreras JA, Goñi J, Risacher SL, Sporns O, Saykin AJ. The structural and functional connectome and prediction of risk for cognitive impairment in older adults. Curr Behav Neurosci Rep. 2015;2(4):234–45. Scholar
  49. 49.
    Damoiseaux JS, et al. Functional connectivity tracks clinical deterioration in Alzheimer’s disease. Neurobiol Aging. 2012;33(4):828.e19–828.e8.28E30. Scholar
  50. 50.
    Contreras JA, Fortunato S, Avena-Koenigsberger A, Risacher SL, West JD, Tallman EF, et al. Resting state network modularity along the prodromal late onset Alzheimer’s disease continuum. Alzheimers Dement. 2017;13(7):P457. Scholar
  51. 51.
    Viviano RP, et al. Aberrant memory system connectivity and working memory performance in subjective cognitive decline. NeuroImage. 2019;185:556–64. Scholar
  52. 52.
    Hayes JM, et al. Subjective memory complaints are associated with brain activation supporting successful memory encoding. Neurobiol Aging. 2017;60:71–80. Scholar
  53. 53.
    Davis SW, et al. Que PASA? The posterior-anterior shift in aging. Cereb Cortex. 2008;18(5):1201–9. Scholar
  54. 54.
    Dumas JA, Kutz AM, McDonald BC, Naylor MR, Pfaff AC, Saykin AJ, et al. Increased working memory-related brain activity in middle-aged women with cognitive complaints. Neurobiol Aging. 2013;34(4):1145–7. Scholar
  55. 55.
    Erk S, et al. Evidence of neuronal compensation during episodic memory in subjective memory impairment. Arch Gen Psychiatry. 2011;68(8):845–52. Scholar
  56. 56.
    Rodda JE, Dannhauser TM, Cutinha DJ, Shergill SS, Walker Z. Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task. Int J Geriatr Psychiatry. 2009;24(8):865–74. Scholar
  57. 57.
    Shokouhi S, et al. The relationship between domain-specific subjective cognitive decline and Alzheimer’s pathology in normal elderly adults. Neurobiol Aging. 2019;81:22–9. Scholar
  58. 58.
    Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755–66. Scholar
  59. 59.
    Newhouse P, Dumas J. Estrogen-cholinergic interactions: implications for cognitive aging. Horm Behav. 2015;74:173–85. Scholar
  60. 60.
    Franzmeier Nicolai AR et al. Functional connectivity associated with tau levels in aging, Alzheimer’s, and small-vessel disease. 2019: Human Amyloid Imaging 2019.Google Scholar
  61. 61.
    • Ingalhalikar M, et al. Sex differences in the structural connectome of the human brain. Proc Natl Acad Sci. 2014;111(2):823. study showed evidence of sex-specific differences in the brain organization. CrossRefPubMedGoogle Scholar
  62. 62.
    Ritchie SJ, Cox SR, Shen X, Lombardo MV, Reus LM, Alloza C, et al. Sex differences in the adult human brain: evidence from 5216 UK Biobank participants. Cereb Cortex. 2018;28(8):2959–75. Scholar
  63. 63.
    van Oijen M, et al. Subjective memory complaints, education, and risk of Alzheimer’s disease. Alzheimers Dement. 2007;3(2):92–7. Scholar
  64. 64.
    Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:112–7.CrossRefGoogle Scholar
  65. 65.
    Zetterberg H. Blood-based biomarkers for Alzheimer’s disease—an update. J Neurosci Methods. 2019;319:2–6. Scholar
  66. 66.
    Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–89. Scholar
  67. 67.
    Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med. 2018;15(1):e1002482. Scholar
  68. 68.
    Klosinski LP, Yao J, Yin F, Fonteh AN, Harrington MG, Christensen TA, et al. White matter lipids as a ketogenic fuel supply in aging female brain: implications for Alzheimer’s disease. EBioMedicine. 2015;2(12):1888–904. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Center for Cognitive Medicine, Department of Psychiatry and Behavioral SciencesVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations